FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988581606> ?p ?o ?g. }

• W2988581606 endingPage "446" @default.
• W2988581606 startingPage "439" @default.
• W2988581606 abstract "Patients with predominant variant histology (VH) of bladder tumors, defined as involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for these patients, the efficacy of standard chemotherapy is limited.To evaluate the activity of preoperative pembrolizumab in patients with muscle-invasive bladder carcinoma (MIBC) and VH, enrolled in PURE-01 study (NCT02736266).In the open-label, single-arm, phase 2 PURE-01 study, three courses of 200 mg pembrolizumab preceding radical cystectomy (RC) were administered in T2-4aN0M0 MIBC patients. The amended study design included patients with predominant VH.Neoadjuvant pembrolizumab and RC.Pathological complete response (pT0) in intention-to-treat population was the primary endpoint. Biomarker analyses included programmed cell-death ligand-1 (PD-L1) expression using the combined positive score (CPS; Dako 22C3 antibody) and comprehensive genomic profiling (FoundationOne assay). Multivariable logistic regression analyses (MVAs) evaluated the histological category (predominant VH vs nonpredominant VH vs pure urothelial carcinoma), tumor mutational burden (TMB) and CPS in association with the pathological response.From February 2017 to June 2019, 114 patients were enrolled; 34 (30%) of them presented with VH, including 19 (17%) with predominant VH. In total, the pT0 rate was 37% (95% confidence interval [CI]: 28-46) and the pT ≤ 1 rate was 55% (95% CI: 46-65). The majority of predominant VH patients presented with squamous-cell carcinoma (SCC; N = 7), and six of seven (86%) had downstaging to pT ≤ 1, with one pT0; two of three lymphoepithelioma-like (LEL) variants had a pT0 response. None of the remaining nine predominant VHs had a response. On MVA, TMB and CPS were associated with both the pT0 and the pT ≤ 1 response, regardless of tumor histology.The updated PURE-01 results confirm the activity of neoadjuvant pembrolizumab in MIBC. Patients with SCC and LEL features may be suitable for neoadjuvant immunotherapy trials. CPS and TMB are the key response predictors irrespective of the histological subtypes.In the PURE-01 study, we have preliminarily evaluated the activity of neoadjuvant pembrolizumab in patients with predominant variant histology (VH). Of these patients, those harboring squamous-cell carcinoma or a lymphoepithelioma-like variant feature had major, although preliminary, pathological responses compared with those with other predominant VHs. Expression of programmed cell-death ligand-1 and tumor mutational burden may predict the pathological response to pembrolizumab, and provide a rationale for selecting patients according to these features instead of the histological bladder cancer subtypes." @default.
• W2988581606 created "2019-11-22" @default.
• W2988581606 creator A5000621664 @default.
• W2988581606 creator A5006746061 @default.
• W2988581606 creator A5012466586 @default.
• W2988581606 creator A5023266580 @default.
• W2988581606 creator A5031550729 @default.
• W2988581606 creator A5032009066 @default.
• W2988581606 creator A5034916881 @default.
• W2988581606 creator A5036320874 @default.
• W2988581606 creator A5038974730 @default.
• W2988581606 creator A5039363062 @default.
• W2988581606 creator A5048165263 @default.
• W2988581606 creator A5054660525 @default.
• W2988581606 creator A5058849092 @default.
• W2988581606 creator A5059157811 @default.
• W2988581606 creator A5061623935 @default.
• W2988581606 creator A5075830981 @default.
• W2988581606 creator A5078216208 @default.
• W2988581606 creator A5078798686 @default.
• W2988581606 creator A5081296401 @default.
• W2988581606 creator A5083331837 @default.
• W2988581606 creator A5086507632 @default.
• W2988581606 creator A5088559019 @default.
• W2988581606 creator A5088809839 @default.
• W2988581606 creator A5090061046 @default.
• W2988581606 date "2020-04-01" @default.
• W2988581606 modified "2023-10-17" @default.
• W2988581606 title "Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies" @default.
• W2988581606 cites W1845099892 @default.
• W2988581606 cites W1972027031 @default.
• W2988581606 cites W2073175347 @default.
• W2988581606 cites W2096998881 @default.
• W2988581606 cites W2099144023 @default.
• W2988581606 cites W2103725052 @default.
• W2988581606 cites W2160981405 @default.
• W2988581606 cites W2301685087 @default.
• W2988581606 cites W2462649057 @default.
• W2988581606 cites W2550294854 @default.
• W2988581606 cites W2588916311 @default.
• W2988581606 cites W2606495925 @default.
• W2988581606 cites W2619249519 @default.
• W2988581606 cites W2756190798 @default.
• W2988581606 cites W2760661635 @default.
• W2988581606 cites W2806413184 @default.
• W2988581606 cites W2886675419 @default.
• W2988581606 cites W2887910828 @default.
• W2988581606 cites W2897581535 @default.
• W2988581606 cites W2947126603 @default.
• W2988581606 cites W2947932644 @default.
• W2988581606 cites W2954357619 @default.
• W2988581606 cites W2987436342 @default.
• W2988581606 doi "https://doi.org/10.1016/j.eururo.2019.10.026" @default.
• W2988581606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31708296" @default.
• W2988581606 hasPublicationYear "2020" @default.
• W2988581606 type Work @default.
• W2988581606 sameAs 2988581606 @default.
• W2988581606 citedByCount "211" @default.
• W2988581606 countsByYear W29885816062019 @default.
• W2988581606 countsByYear W29885816062020 @default.
• W2988581606 countsByYear W29885816062021 @default.
• W2988581606 countsByYear W29885816062022 @default.
• W2988581606 countsByYear W29885816062023 @default.
• W2988581606 crossrefType "journal-article" @default.
• W2988581606 hasAuthorship W2988581606A5000621664 @default.
• W2988581606 hasAuthorship W2988581606A5006746061 @default.
• W2988581606 hasAuthorship W2988581606A5012466586 @default.
• W2988581606 hasAuthorship W2988581606A5023266580 @default.
• W2988581606 hasAuthorship W2988581606A5031550729 @default.
• W2988581606 hasAuthorship W2988581606A5032009066 @default.
• W2988581606 hasAuthorship W2988581606A5034916881 @default.
• W2988581606 hasAuthorship W2988581606A5036320874 @default.
• W2988581606 hasAuthorship W2988581606A5038974730 @default.
• W2988581606 hasAuthorship W2988581606A5039363062 @default.
• W2988581606 hasAuthorship W2988581606A5048165263 @default.
• W2988581606 hasAuthorship W2988581606A5054660525 @default.
• W2988581606 hasAuthorship W2988581606A5058849092 @default.
• W2988581606 hasAuthorship W2988581606A5059157811 @default.
• W2988581606 hasAuthorship W2988581606A5061623935 @default.
• W2988581606 hasAuthorship W2988581606A5075830981 @default.
• W2988581606 hasAuthorship W2988581606A5078216208 @default.
• W2988581606 hasAuthorship W2988581606A5078798686 @default.
• W2988581606 hasAuthorship W2988581606A5081296401 @default.
• W2988581606 hasAuthorship W2988581606A5083331837 @default.
• W2988581606 hasAuthorship W2988581606A5086507632 @default.
• W2988581606 hasAuthorship W2988581606A5088559019 @default.
• W2988581606 hasAuthorship W2988581606A5088809839 @default.
• W2988581606 hasAuthorship W2988581606A5090061046 @default.
• W2988581606 hasConcept C121608353 @default.
• W2988581606 hasConcept C126322002 @default.
• W2988581606 hasConcept C126894567 @default.
• W2988581606 hasConcept C143998085 @default.
• W2988581606 hasConcept C203092338 @default.
• W2988581606 hasConcept C2775910329 @default.
• W2988581606 hasConcept C2777546739 @default.
• W2988581606 hasConcept C2777701055 @default.
• W2988581606 hasConcept C2780057760 @default.
• W2988581606 hasConcept C2780352672 @default.

• next